Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iMagic Injection in Relapsed/Refractory Hematologic Malignancies
NCT07802756Phase 1Not yet recruiting
- Sponsor
- Immunofoco
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of iMagic Injection in non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) (2 arms), sponsored by Immunofoco. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 24 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
iMagic Injection
03
Conditions
non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07802756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802756.